UCB SA (OTCMKTS:UCBJY) Short Interest Up 668.9% in August

UCB SA (OTCMKTS:UCBJY) was the recipient of a large increase in short interest in the month of August. As of August 31st, there was short interest totaling 14,956 shares, an increase of 668.9% from the August 15th total of 1,945 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 67,990 shares, the short-interest ratio is presently 0.2 days.

UCB Price Performance

OTCMKTS UCBJY opened at $117.06 on Friday. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.38 and a quick ratio of 1.04. The company has a 50 day simple moving average of $131.47 and a 200-day simple moving average of $141.33. UCB has a 52-week low of $114.53 and a 52-week high of $168.76.

Wall Street Analysts Forecast Growth

Several research analysts have commented on UCBJY shares. Zacks Research upgraded shares of UCB from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 4th. Barclays downgraded shares of UCB from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 15th. Finally, Jefferies Financial Group raised shares of UCB from a “moderate sell” rating to a “hold” rating in a research note on Monday, August 3rd. Two equities research analysts have rated the stock with a Strong Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, UCB has an average rating of “Buy”.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on developing and commercializing medicines for people living with severe neurological and immunological diseases. The company operates internationally, serving patients and healthcare providers across North America, Europe and other global markets.

Its neurology portfolio includes treatments such as Keppra and Briviact for epilepsy, Vimpat for partial-onset seizures and Fintepla for certain severe seizure disorders. In immunology, UCB markets Cimzia for conditions including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and Crohn’s disease, as well as Bimzelx for several inflammatory skin and joint conditions.

UCB traces its origins to 1928, when it was established in Belgium as Union Chimique Belge.